Pregled bibliografske jedinice broj: 1173618
Development of stem cell clinical trials in Europe between 2008 and 2012: Political and financial influences
Development of stem cell clinical trials in Europe between 2008 and 2012: Political and financial influences // 25th FIAMC Congress / Markeljević, Jasenka (ur.).
Zagreb, 2018. str. 1-1 (poster, recenziran, sažetak, ostalo)
CROSBI ID: 1173618 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Development of stem cell clinical trials in Europe
between 2008 and 2012: Political and financial
influences
Autori
Blažević, Sofia Ana ; Soler-Ferreria, Dana ; San- Martín, Montserrat ; Vivanco, Luis
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
25th FIAMC Congress
/ Markeljević, Jasenka - Zagreb, 2018, 1-1
Skup
25th FIAMC Congress
Mjesto i datum
Zagreb, Hrvatska, 30.05.2018. - 02.06.2018
Vrsta sudjelovanja
Poster
Vrsta recenzije
Recenziran
Ključne riječi
stem cells, research, Europe
Sažetak
Objectives: The aim was to measure the political and financial influences on the development of European stem cell research. Methods: We performed a careful analysis of the EudraCT database looking at clinical trials using stem cells carried out between 2008 and 2012. Different variables were measured (country, trial status, type of funds, trial phase, clinical procedure, patients, ages, type of stem cells, and type of clinical targets). Chi-squared tests were applied by countries, p values <0.05 were considered statistically significant. Results: During the period between 2008 and 2012, 274 trials were conducted in 19 European countries. 252 (92%) trials received grants from 13 European countries, of which 164 were publicly funded. The five countries with higher participation in trials (179) and greater number of grants (209) were: Germany, Italy, United Kingdom, Spain and The Netherlands. In all cases, including both private and public grants, Spain revealed a different behaviour from all other countries (p<0.05), reflecting a political push to favour this particular line of research. Seven different types of adult stem cells were used in 264 trials, while the remaining 10 used umbilical cord stem cells. Conclusions: Four of the five countries with greater participation in clinical trials with stem cells have legal frameworks permitting the use of embryonic stem cells. However, none of them registered any clinical trial with this kind of cells. Consequently, all countries except Spain, made similar adjustments in their public funding politics, possibly because of the financial crisis.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
POVEZANOST RADA
Ustanove:
Prirodoslovno-matematički fakultet, Zagreb
Profili:
Sofia Ana Blažević
(autor)